Trajenta Articles
Once again, no proof of added benefit found for Boehringer/Lilly's Trajenta by Germany's IQWiG
13 December 2012
Added benefit of Trajenta not proven, says German agency
10 January 2012
Showing 1-4 of 4 articles
- 1
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
